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The p53 tumour suppressor gene regulates a DNA damage-triggered
G1 checkpoint (Hartwell and Kastan, 1994). p53-dependent growth
arrest occurs upon transcriptional activation of p21, which in
turn inhibits cyclin-dependent kinase-mediated phosphorylation of
retinoblastoma protein (pRB) (Shaw et al, 1992; Clarke et al, 1993;
Hartwell and Kastan, 1994). In contrast, loss of retinoblastoma gene
(RB) function, both in cultured cells and in animals, results in inap-
propriate S-phase entry and apoptosis (Morgenbesser et al, 1994;
Almasan et al, 1995; Macleod et al, 1996). RB, therefore, plays an
important role in the regulation of p53-mediated apoptosis.
Induction of p53-mediated apoptosis is enhanced by: lack of
expression of p21, an upstream regulator of RB (Waldman et al,
1996); viral E1A protein, which binds and inactivates pRB (White
et al, 1991); and overexpression of E2F-1, a downstream protein
whose action to drive the G1/S-phase transition is regulated by RB
(Kowalik et al, 1995; Qin et al, 1994). Conversely, coexpression of
functional RB with concomitant overexpression of wild-type (wt)
p53 can overcome p53-dependent apoptosis in HeLa cells (Haupt
et al, 1995). All of these observations suggest that p53 and RB
play opposing roles in the control of apoptosis, that is, RB serves
as a barrier to p53-mediated apoptosis by regulating the G1/S-
phase transition. There is little direct evidence, however, to
substantiate this hypothesis, especially in human cancer cells.
We previously reported that the stably transfected RB gene func-
tions as a growth suppressor in HTB9 human bladder carcinoma
cells, which carry a mutation of the p53 gene at codon 280 and lack
RB expression (Takahashi et al, 1991). In the present study, we
employed one of these clones to obtain double transfectants that
coexpressed RB and wt p53. This study addresses the potential role
of RB in the regulation of p53-mediated apoptosis by using wt
p53/RB variants derived from parental HTB9 cells. We show by
cell cycle analyses and soft agar assays that the growth-arrest
function of RB leads to suppression of wt p53-mediated apoptosis.
MATERIALS AND METHODS
Reagents
RPMI 1640 medium was purchased from GIBCO/BRL
(Rockville, MD, USA). Fetal bovine serum (FBS) was purchased
from Whittacker (Walkersville, MD, USA). Ca2+- and Mg2+-free
phosphate-buffered saline (PBS), etoposide, propidium iodide (PI)
and ribonuclease A (RNase A) were purchased from Sigma
Chemical Co (St. Louis, MO, USA).
Mice
Athymic 4-week-old Balb/c nude mice were purchased from Clea
(Tokyo, Japan). The mice were maintained according to institu-
tional guidelines in accordance with the National Institutes of
Health (1996).
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The parental HTB9 cells and the stably RB-transfected clone,
H/RB (Takahashi et al, 1991) were cultured at 37° C in RPMI
1640/25 mM HEPES medium supplemented with 10% FBS and
1% penicillin-streptomycin in an atmosphere of 5% CO2.
Stable transfection of wt p53
We constructed a wt p53-expression plasmid, pSEp53/hyg (Figure
1), by inserting the isolated wt p53 cDNA and its entire coding
region under control of the SV40 early promoter into expression
vector pAGE208 (data not shown). H/RB cells were plated onto
100-mm culture dishes at a density of 5 × 105 per dish and trans-
fected by using a mammalian transfection kit (Stratagene, La Jolla,
CA, USA) with the plasmid digested with Fsp I. After 3 weeks,
the hygromycin B-resistant clones were maintained separately in
medium containing hygromycin B (200 µ g ml–1) and were propa-
gated for further analysis. In another transfection experiment, the
wt p53-expression plasmid pCDM8-p53/neo, in which expression
of the p53 gene is under the control of the CMV promoter (Tamura
et al, 1995), was digested with Sca I and transfected into HTB9
cells, yielding G418-resistant clones (200 µ g ml–1).
Reverse transcriptase-initiated polymerase chain
reaction (RT-PCR) and cDNA sequencing
Total cytoplasmic RNA was isolated according to the guanidium
thiocyanate method (Chomczynski and Sacchi, 1987). For cDNA
sequence analysis, cDNA was synthesized from 1 µ g of total RNA
by using a First Strand Synthesis Kit (Pharmacia, Piscataway, NJ,
USA). Since parental HTB9 cells are known to have a missense
mutation at codon 280, a region corresponding to exons 4 through
10 of the p53 gene was amplified from the cDNA by PCR using a
set of primers, 5′ -CTTCTGTCCCTTCCCAGAAAACC-3′ and 5′ -
CCTCATTCAGCTCTCGGA ACATCTCG-3′ . cDNA sequencing
was performed by using an fmol cycle sequencing kit (Promega,
Madison, WI, USA) with a primer corresponding to the 3′ -end
of exon 7 (5′ -XTAGTGTGGTGGTGCCCTATGAGCCG-3′ , X:
Biotin). The sequence ladder was detected by using a Sequencing
High chemiluminescent detection kit (Toyobo, Osaka, Japan).
Using primers, 5′ -ATGATGTGTTCCATGTATGGC-3′ and 5′ -
AATATAGATGTTCCCTCCAGG-3′ , we performed RT-PCR to
amplify the RB gene from cDNA.
Northern blot analysis
RNA blotting was performed as described by Thomas (1980). The
membranes were then hybridized with a digoxigenin-labelled, 1.3-
kb p53-RNA probe by using a DIG RNA-labeling kit (Boehringer
Mannheim GmbH, Mannheim, Germany). Endogenous and
exogenous p53-mRNAs were detected by using a DIG nucleic
acid detection kit (Boehringer Mannheim GmbH).
Immunocytochemistry
Cells were cultured at subconfluence in a Lab-Tek chamber slide
(Nunc, Naperville, IL, USA). After being fixed with neutral-
buffered formalin, the cells were permealized for 5 min in PBS
containing 0.1% Triton X-100. The endogenous peroxidase
activity was blocked by incubating the cells for 10 min in 3%
H2O2. The cells were then incubated at room temperature for 2 h
with the anti-RB antibody (MBL Inc, Nagoya, Japan) or with the
anti-p16INK4A antibody (Santa Cruz, Santa Cruz, CA, USA) and for
30 min with biotinylated horse anti-mouse IgG. The slide was
incubated for 30 min with the avidin–biotin peroxidase complex
reagent (Vecstatin ABC kit, Vector Laboratories, Burlingame, CA,
USA). Diaminobenzidine (0.05%) was used as the final chromo-
gen, and haematoxylin was used as the nuclear counterstain.
Immunoblotting
Cell extracts containing 100 µ g protein were separated electro-
phoretically by using either 5% or 4–20% SDS-PAGE (Daiichi
Pure Chemicals, Tokyo, Japan). The proteins were transferred onto
a PVDF membrane (Immobilon-P; Millipore, Tokyo, Japan) for
2 h at 200 mA. The membrane was blocked with 5% nonfat dried
milk in phosphate-buffered saline (PBS) containing 0.1% Tween-
20. For detecting RB, the anti-RB monoclonal antibody (MBL,
Nagoya, Japan) was used as a primary antibody. For p16, the anti-
p16INK4A antibody (PharMingen, San Diego, CA, USA) was used
as a primary antibody. The secondary antibody used for both RB
and p16, was horseradish peroxidase-conjugated sheep anti-mouse
IgG (H + L) (Amersham, Buckinghampshire, UK). The antibody
complexes were detected by using an enhanced chemilumines-
cence system (Amersham).
Cell-cycle analysis
Cells (7 × 104) in complete medium containing 10% FBS were
seeded on sterile glass slides. After 24 h of plating, the cells were
cultured in 100-mm dishes in medium without 10% FBS or with
10% FBS as a control. Etoposide, an inhibitor of DNA topoiso-
merase II that ultimately causes apoptotic cell death by p53-depen-
dent pathways (Clarke et al, 1993), was dissolved in dimethyl
sulphoxide, added to the medium containing 10% FBS at a final
concentration of either 6 or 30 µ g ml–1, and allowed to react for up
to 48 h before fixation. After 96 h, the cells growing on the slides
were fixed in 99% ethanol at 4° C overnight, stained with a PI
1040 H Shinohara et al
British Journal of Cancer (2000) 83(8), 1039–1046 © 2000 Cancer Research Campaign
PSE
Xba I
p53
Xba I
poly (A)
Hyg
r
Ptk
Amp
r
Fsp I
Fsp I
pSEp53/hyg
(7.6kb)
Figure 1 Schematic presentation of wt p53 expression plasmid.
p53 = wt p53-cDNA insert; Hygr = hygromycin B-resistant gene;
Ptk = phosphothymidine kinase promoter; Ampr = ampicillin-resistant gene;
PSE = SV40 early promoter(50 µ g ml–1) solution containing 100 µ g ml–1 of RNase A, and then
incubated at 37° C for 30 min. Cells that had adhered to the slides
in an area measuring 5 × 5 mm were scanned with an LSC101
laser scanning cytometer (Olympus Optics Co, Tokyo, Japan)
nuclear debris and overlapping nuclei were gated out by statistical
filters (Kamentsky and Kamentsky, 1991). The percentage of
viable cells was calculated by using the following formula:
viability (%) = A/B × 100, where A is the number of cells in
treated cultures and B is the number of cells in the control cultures.
The statistical significance of the differences in viability was
determined by performing unpaired Student’s t-test. DNA ploidy
was determined by analysing DNA histograms that were generated
by using computer software, as in flow cytometry, and the cells
whose ploidy was abnormal were recalled to observe their nuclear
morphology.
Soft agar assay
Cells were seeded at a density of 1 × 105 per 60-mm dish in RPMI
medium containing 0.33% agarose and 20% FBS. The medium
was replenished every 7 days. The colonies (>50 cells each) were
scored after 3 weeks, and the growth results were calculated as the
average of three culture dishes per cell strain.
Tumorigenesis
Cultures of parental and transfected tumour cells in their exponen-
tial growth phase were harvested by a brief exposure to a solution
of 0.25% trypsin and 0.1% EDTA. The cell suspension was
pipetted to produce a single-cell suspension, and then washed and
resuspended in PBS. Cells (1 × 107 in 0.2 ml PBS) were injected
subcutaneously into the right flank of a nude mouse. Tumour
volume was measured every 1–2 weeks for 6 weeks. To re-estab-
lish a line from the tumours in culture the tumours were minced
under sterile conditions and transferred to culture dishes in the
presence of complete medium containing either G418 or
hygromycin.
DNA sequencing
Alterations with coding sequences of the p16 gene were tested by
sequencing of the PCR amplified gene fragments by using a
LI-COR Model 4000 DNA sequencer (Aloka, Tokyo, Japan)
following the manufacturer’s protocol. Each PCR product was
cloned into the TA cloning vector and its sequence was analysed in
each of three clones.
RESULTS
Characterization of transfected clones
Nineteen separate hygromycin B-resistant clones were obtained by
transfecting the wt p53 gene into the H/RB cells that we had previ-
ously isolated by transfecting the RB gene into parental HTB9
cells (Takahashi et al, 1991). Transcripts from eight clones were
sequenced to identify the exogenous wt-p53 allele after RT-PCR.
Both wt and mutant p53 sequences that corresponded to codon 280
were identified in six clones, namely H/RB/p53-1, -2, -4, -5, -7,
and -8. Representative results for HTB9 and one of these clones,
H/RB/p53-1, are shown in Figure 2A. The RNAs of these clones
were also analysed by Northern blotting to identify exogenous p53
mRNA. The exogenous wt p53-mRNA (2.1-kb), which could be
distinguished from the mutant p53-mRNA (2.8 kb) by its size, was
also detected by Northern blotting except in the H/RB/p53-3 and
-6 clones (data not shown). Also confirmed was the fact that, like
H/RB cells, all of the eight clones were resistant to G418 at a dose
of 400 µ g ml–1. RT-PCR revealed that the expression levels of the
exogenous RB gene in wt p53 transfectants were persistent (Figure
2B), although the levels were relatively lower in H/RB/p53-2 and
-8 cells by Northern blotting (data not shown). Furthermore, as
measured by immunostaining with monoclonal anti-RB antibody,
nuclear staining of pRB in H/RB/p53-1, -2, -5, and -8 clones was
similar to that in the H/RB cells. The staining pattern of
H/RB/p53-1 and H/RB cells is represented in Figure 2C. The
expression levels of exogenous RB protein were mostly equivalent
among the RB-transfected clones analysed by immunoblotting
using anti-RB monoclonal antibody. The representatives are
shown in Figure 2D. Therefore, for subsequent studies, we
selected H/RB/p53-1 as a representative cotransfectant with RB
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Figure 2 Identification of exogenous wt p53 and RB gene expression
(A) RT-PCR sequencing analysis of parental HTB9, H/p53, and H/RB/p53-1
cells. The sequence corresponding to codon 280 is indicated. Both the wt
and the mutant p53 sequences were identified in H/p53 and in H/RB/p53-1
cells. (B) RT-PCR for detecting RB gene expression (upper panel) and
glyceraldehyde phosphate dehydrogenase (GAPDH) gene expression (lower
panel). (C) Demonstration of nuclear RB expression
by immunocytochemistry using anti-RB antibody (magnification × 400).
(D) Demonstration of RB expression by Western blottingand wt p53, and H/RB/p53-3 was used as a negative control for wt
p53 expression.
We also transfected the wt p53 expression plasmid into parental
HTB9 cells to obtain p53+/RB– clones. By using RT-PCR and
cDNA sequencing, we identified exogenous wt p53 in three G418-
resistant clones. Representative data for one of these clones,
H/p53, are shown in Figure 2A.
The status of the p16 gene, which is one of the frequently
mutated genes in the RB pathway, was also assessed by Western
blotting and immunocytochemical staining (Figure 3). Western
blotting showed that the expression level of the p16 protein was
maintained in all the transfected clones. These data were also
confirmed at the single-cell level by immunocytochemical staining
using the anti-p16INK4A antibody. Furthermore, sequence analysis
of the genomic p16 locus was also performed, and revealed no
mutation in exons 1, 2 and 3 of the p16 gene (data not shown).
RB prevents cells from losing viability when deprived
of serum
We examined whether cell viability was associated with exoge-
nous expression of the wt p53 and/or RB genes by using laser
scanning cytometry (LSC). In control cultures that were incubated
for 96 h with normal medium containing 10% FBS, the number of
viable cells transfected with the wt p53 and/or RB genes was
significantly lower than that of parental cells (P < 0.01); the mean
numbers of viable HTB9, H/p53, H/RB, H/RB/p53-1, and
H/RB/p53-3 cells were calculated to be 15187 ± 426, 9271 ± 713,
7860 ± 922, 8044 ± 323, and 7166 ± 197, respectively. Table 1
shows the viability of these cells when they were incubated with
FBS-free medium for 72 h before fixation. The viability of the
H/p53 cells decreased significantly, as compared to that of HTB9
cells. In sharp contrast, the H/RB, H/RB/p53-1, and H/RB/p53-3
cells were much more resistant to the effects of serum deprivation.
RB suppresses S-phase entry and apoptosis in cells
exposed short-term to etoposide
We induced apoptosis by treating the cells with etoposide, a DNA-
strand breakage agent (Table 1, Figure 4). There were no signifi-
cant differences in the viability of the cells that were treated with
low-dose (6 µ g ml–1) etoposide for 6 h before fixation. LSC
revealed that, in all cell groups, more than 40% of the cells reached
S-phase, whereas cells in the G1-phase were much fewer when
compared to the controls. Notably, the cell fraction in early S-
phase was observed in parental HTB9 cells and in the wt p53-
expressive clones H/p53 and H/RB/p53-1 but not in the purely
pRB-positive clones H/RB and H/RB/p53-3. When treated with
high-dose (30 µ g ml–1) etoposide, the viability of the H/p53 cells
significantly decreased, as compared to that of the HTB9 cells.
The H/p53 cells had a characteristic DNA histogram, showing
cells in the sub-G1-phase and in a higher DNA ploidy cycle (i.e.
additional-S-phase), which is consistent with the apoptotic process
reported previously (Waldman et al, 1996). In contrast, the pRB-
expressive cells, including the wt p53-positive H/RB/p53-1 cells,
were much more resistant to the etopside treatment, and the cell
population in the sub-G1- or additional-S-phase was insignificant
(Figure 4). Exogenous expression of RB apparently protected
human bladder carcinoma cells from p53-dependent apoptosis
after short-term (6 h) exposure to etoposide.
RB induces growth arrest at the G2/M-phase in cells
exposed long-term to etoposide
We examined the effects of long-term exposure of etoposide on
apoptotic cell death (Table 1, Figure 5). The viability of the H/p53
cells significantly decreased when the cells were treated for 48 h
with 6 µ g ml–1 etoposide, as compared to that of the HTB9 cells.
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Figure 3 Expression of the p16INK4A protein before and after transfection.
(A) Western blotting of parental HTB9, H/p53, H/RB, H/RB/p53-1 and
H/RB/p53-3 cells. (B) Immunocytochemical staining. Control = without
primary antibody; HTB9 and H/RB/p53-1 = with the p16INK4A antibody
Table 1 Viability of human bladder carcinoma cells deprived of serum or treated with etoposide
Cell Expression status Viability (%)a
strain p53 RB FBS free Etoposide
6 µ g ml–1 (6 h) 30 µ g ml–1 (6 h) 6 µ g ml–1 (48 h)
HTB9 mt – 25.9 ± 1.6 81.2 ± 1.5 61.3 ± 2.3 8.5 ± 7.4
H/p53 wt/mt – 16.3 ± 0.7c 82.0 ± 2.6 36.9 ± 3.9c 2.4 ± 0.3c
H/RB mt + 60.3 ± 3.2c 85.0 ± 2.9 87.0 ± 2.9c 16.3 ± 14.1b
H/RB/p53-1 wt/mt + 61.9 ± 2.0c,d 84.4 ± 9.6 81.5 ± 1.3c,d 13.7 ± 11.9b,d
H/RB/p53-3 mt + 56.6 ± 5.4c 89.1 ± 2.6 85.9 ± 3.0c 16.9 ± 14.6b
a The percentage of viable cells was calculated by using the following formula: viability (%) = A/B × 100, where A is the number of cells in
the treated cultures and B is the number of cells in the control cultures. Results are presented as means ± SD of five different areas of the
slides; b P < 0.01, as compared to HTB9 cells; c P < 0.001, as compared to HTB9 cells; d P < 0.0001, as compared to H/p53 cells.
FBS = fetal bovine serum.Many of H/p53 cells were found to be dead or dying by phase-
contrast microscopy (Figure 5A). In contrast, the pRB-expressive
cells, including the wt p53-positive H/RB/p53-1 cells, were much
more resistant to this treatment. LSC revealed that the pRB-
expressive H/RB and H/RB/p53-1 cells were arrested at the G2/M-
phase, regardless of p53 status. The peak of the DNA histogram of
the pRB-nonexpressive parental HTB-9 and H/p53 cells was
shifted to the left, however, and the cells had accumulated in an
S-like state. Furthermore, a large accumulation of H/p53 cells had
entered the additional-S-phase (Figure 5B). Representative H/p53
cells with sub-G1, S-like, and additional-S DNA content were
recalled and photographed (Figure 5C). Fragmented and highly
condensed chromatin was seen in sub-G1 cells, whereas cells in
the additional-S-phase had large nuclei. In contrast to H/RB/p53-1
cells in the G2-phase, cells defined as being in an S-like state
exhibited very little residual DNA staining, probably because of
the loss of degraded DNA from cells in the advanced stages of
apoptosis.
RB increases colony formation in soft agar
We examined the ability of human bladder carcinoma cells to form
colonies in soft agar to determine the effects of anchorage depen-
dency on induction of apoptosis. As shown in Table 2, the H/p53
Regulation of apoptosis by the RB and p53 genes 1043
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Figure 4 Laser scanning cytometric analysis of human bladder carcinoma
cells treated with or without etoposide for 6 h before fixation. The histograms
represent DNA content and indicate cells in the G1-, S-, or G2/M-phase of
the cell cycle as determined by staining with propidium iodide. Note the cell
fraction in early S-phase (arrows) observed in parental HTB-9, H/p53, and
H/RB/p53-1 cells treated with 6 µ g ml–1 of etoposide
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Figure 5 Apoptosis in human bladder carcinoma cells treated with 6 µ g ml–1
of etoposide for 48 h before fixation. (A) Cell viability as measured by phase-
contrast microscopy (magnification × 400). (B) Histograms representing DNA
content as measured by LSC. Most of the H/RB and H/RB/p53-3 cells were
arrested at the G2/M-phase, whereas the peak of the histogram was shifted
to the left in parental HTB-9 and H/p53 cells. Small squares (   ) indicate cells
recalled for the photographs shown in C. (C) Representative H/p53 cells that
had sub-G1 (sG1)-, S-like (S)-, and additional-S (adS)-phase DNA content,
and H/RB/p53-1 cells that had G2-phase DNA content. Cells were recalled
from the DNA histogram, and photographed by a 3CCD camera attached to
the microscope of the cytometer (magnification × 400)cells almost completely lost the ability to from colonies in soft
agar. In contrast, the number of colonies formed by the pRB-
expressive H/RB, H/RB/p53-1, and H/RB/p53-3 clones, were
significantly greater than those formed by parental HTB9 cells.
RB inhibits tumorigenesis in nude mice
In the final set of experiments, we investigated the effect of stable
RB or p53 transfection, or both, on the tumorigenicity of human
bladder carcinoma cells (Table 2). All of the mice injected with
parental HTB9 cells produced tumours that grew progressively. In
contrast, none of mice injected with H/p53 cells produced
tumours. As we reported previously (Takahashi et al, 1991), the
H/RB cells did not exhibit tumorigenicity in nude mice, nor did
the H/RB/p53-1 cells coexpressing wt p53 and RB. These results
indicated that RB allows suppression of tumorigenesis, regard-
less of p53 status. Unexpectedly, all five animals injected with
H/RB/p53-3 cells formed tumours. Histopathological analysis
disclosed that tumours derived from the H/RB/p53-3 cells retained
the malignant characteristics of the parental cells with moderate
differentiation (data not shown). Cells from each of the tumours
that were re-established in cultures were found to have signifi-
cantly lower expression of RB mRNA, as compared with origi-
nally injected cells, in addition to the negative expression of wt
p53 mRNA (data not shown).
DISCUSSION
Despite the strong inhibitory effects of tumour suppressor genes
on cell growth, the isolation of wt p53- or RB-transfected clones
by using a plasmid has occasionally been successful (Takahashi
et al, 1991; Tamura et al, 1995). In this study, we successfully
isolated, for the first time, clones that stably express both wt p53
and RB under the control of noninducible promoters in human
carcinoma cells that carry a mutation of the p53 gene and lack RB
expression. Our data demonstrate that exogenous coexpression of
pRB can suppress wt p53-mediated apoptosis in cells deprived of
serum or treated with etoposide. These findings are also supported
by soft agar assays that demonstrated that exogenous expression of
pRB is sufficient to promote colony formation, which overcomes
the inability of anchorage-independent cellular growth mediated
by wt p53.
RB is an important cell-cycle regulator, acting to control the
G1/S-phase transition (Bartek et al, 1997). Absence of RB func-
tion is known to allow synthesis of gene products required for S-
phase entry (Almasan et al, 1995) and to activate p53-dependent
apoptosis (Morgenbesser et al, 1994; Almasan et al, 1995;
Macleod et al, 1996). At the molecular level, phosphorylation of
pRB results in the activation of E2F transcription factors, which
in turn activate the transcription of several S-phase genes
including cyclin E, cyclin D, and c-myc (Yamasaki, 1998).
Interestingly, recent studies have demonstrated paradoxical
roles for E2F-1 in the induction of p53-dependent apoptosis
(Qin et al, 1994; Kowalik et al, 1995; Pan et al, 1998; Tsai et al,
1998). Furthermore, overexpression of E2F-1 leads to increased
levels of p53, and the apoptotic effect of E2F-1 can be overcome
through coexpression of MDM2, a ubiquitin-like inhibitor of
p53 (Kowalik et al, 1998). The sequence of evidence indicates
that p53-dependent apoptosis is accelerated by S-phase entry,
which is triggered by activation of E2F-1 resulting from loss of
RB function. Our data also show that exogenous expression of
pRB is sufficient to suppress apoptosis induced by serum depri-
vation or exposure to etoposide in wt p53-expressive cells.
Moreover, LSC followed by treatment with low-dose etoposide
demonstrated that the cell fraction in early S-phase appears in
the wt p53-positive clones, regardless of RB status, but not in
the purely pRB-positive clones. These results suggest that
balanced levels of a series of molecules (e.g. E2F-1), when
regulated by both p53 and RB, may control successful entry into
S-phase.
The E2F-1 target genes that act upstream of p53 have yet to be
identified. One candidate is p19ARF, which can be induced by
E2F-1 (DeGregori et al, 1997) and can cause p53 stabilization by
inhibiting MDM2 (Pomerantz et al, 1998). We are currently
investigating whether the levels of p19ARF are affected in our
transfectants.
Agents, such as etoposide, that characteristically cause DNA
strand breakage induce cellular growth arrest at two well-defined
checkpoints, the G1/S and G2/M boundaries (Del Bino and
Darzynkiewicz, 1991; Wyllie et al, 1996), and prevent cells from
initiating either DNA synthesis or mitosis in the presence of strand
breaks. Our LSC data that showed how cells treated with etoposide
for 48 h accumulated at the G2/M-phase before apoptotic cell
death (Figure 4), therefore, are reasonable and consistent with the
results of previous studies involving HCT116 human colorectal
cancer cells (Waldman et al, 1996) and human lymphocytic
leukaemic MOLT-4 cells (Del Bino and Darzynkiewicz, 1991).
Accumulation of p53 in cells arrested at the G2/M checkpoint also
may be sufficient to accelerate apoptosis (Haapajärvi et al, 1995).
Our results show that H/p53 cells, but not H/RB/p53-1 cells, are
more susceptible to apoptosis and exhibit a characteristic DNA
histogram, some H/p53 cells were arrested in the sub-G1- and
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Table 2 Growth in soft agar and tumorigenicity of human bladder carcinoma cells transfected with the wt p53 or
RB gene or both
Cell strain Expression status Colonies Mice with tumours/ Average tumour
p53 RB in soft agara mice injectedb sizec (mm3)
HTB9 mt – 299 3/3 74.2
H/p53 wt/mt – 6 0/3 0
H/RB mt + 702 0/4 0
H/RB/p53-1 wt/mt + 562 0/5 0
H/RB/p53-3 mt + 788 5/5 33.6
a Cells were seeded at a density of 1 × 105 per 60-mm dish in RPMI medium containing 0.33% agarose and 20%
fetal bovine serum. The values were calculated as the average of three culture dishes per cell strain; b Nude mice
were injected with 1 × 107 cells into the subcutis of the right flank; c Cubic volumes are based on three-
dimensional measurements of the tumours.ectopic S-phase (S-like and additional-S). The specific role of RB
in the suppression of apoptosis through G2/M arrest is under
investigation.
Recent work on the type I insulin-like growth factor receptor,
which allows cancer cells to maintain unregulated growth and to
resist apoptosis, has demonstrated that tumorigenesis in nude
mice is strictly dependent on the fraction of cells that escape apop-
tosis (Resnicoff et al, 1995; Singleton et al, 1996). Our results,
however, indicate that exogenous RB expression is involved in the
reduction of tumorigenesis, suggesting that the growth-arrest
function of RB may be employed, not only to prevent apoptosis,
but also to suppress tumour growth. Since pRB is known to repress
E2F transcriptional activity and since overexpression of E2F is
sufficient for cell-cycle progression, pRB apparently suppresses
tumour growth in part by repressing E2F-mediated transcription
(Yamasaki et al, 1998).
Quantitation of apoptosis is a critical part of the assay, and
may not be easily achieved especially for attached cells.
However, even by using a laser scanning cytometer, quantitation
of sub-G1 cells does not represent total apoptotic cells, due to
detachment of apoptotic cells from the bottom of the culture
flasks. Although we confirmed DNA ladder formation in
detached cells from the supernatant, it was not quantitive. One of
the reasons why we used laser scanning cytometry is its capa-
bility to assess cell viability and morphology, which should also
provide information on the rate of cell proliferation in certain
populations of the cell cycle. This allowed us to normalize the
number of cells. For example, the difference in the number of
expected dividing cells between etoposide-treated and non-
treated groups for 6 h was less than 5%. Therefore, the difference
in the number of remaining cells can mostly be considered due to
apoptosis.
Some investigators have proposed that RB can serve as a mole-
cular switch to determine whether the activation of wt p53 will
lead to growth arrest or to apoptosis (Qin et al, 1994; Haupt et al,
1995; Waldman et al, 1996). Our present findings clearly demon-
strate that induction of functional RB results in suppression of wt
p53-mediated apoptosis in human bladder cancer cells. Our results
also suggest that apoptosis possibly occurred after the cells
continued cycling and entered the S-phase and that RB possibly
had an anti-apoptotic function by providing the genetically
damaged cells with sufficient growth arrest. These possibilities
may explain our in vivo data that showed how exogenous RB erad-
icates tumorigenicity despite inhibition of apoptosis. We believe
our transfectants from the human bladder carcinoma cell line
HTB9 will be a valuable model for directly analysing the mecha-
nism of apoptosis and for testing the differential sensitivity of
tumour cells, with or without wt p53 or RB expression, to various
anticancer agents.
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